A Randomized, Multicenter, Double-Blind, Flexibly-dosed, Efficacy and Safety Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Escitalopram (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors AbbVie; Allergan
- 23 Sep 2021 Status changed from active, no longer recruiting to completed.
- 19 Jul 2021 Planned End Date changed from 2 Jul 2021 to 20 Sep 2021.
- 19 Jul 2021 Planned primary completion date changed from 2 Jul 2021 to 20 Sep 2021.